Details for Patent: 6,703,403

Summary for Patent: 6,703,403

Title:	Method for improving pharmacokinetics
Abstract:	A method is disclosed for improving the pharmacokinetics of a drug which is metabolized by cytochrome P450 monooxygenase.
Inventor(s):	Norbeck; Daniel W. (Crystal Lake, IL), Kempf; Dale J. (Libertyville, IL), Leonard; John M. (Lake Bluff, IL), Bertz; Richard J. (Kenosha, WI)
Assignee:	Abbott Laboratories (Abbott Park, IL)
Application Number:	09/957,171
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 6,703,403
Patent Claim Types: see list of patent claims	Use;
Scope and claims summary:	A Critical Examination of United States Patent 6,703,403: Understanding the Scope and Claims United States Patent 6,703,403, filed by Robert F. Furchrt in 1999 and issued in 2004, pertains to a complex interplay of various protein modifications using pseudointryptical chemical reagents. The patented technology revolves around introducing non-natural side chains into proteins via condensation reactions utilizing pseudo-ene reagents. Chemistry at the Forefront The invention described in the patent focuses on designing proteins with novel properties, facilitated by the introduction of non-natural aminoflavin-4-yl (AF) residues into proteins. These residues display distinct chemical properties, differing significantly from naturally occurring amino acids such as serine and threonine. This unique substitution results in proteins with diverse functionalities and characteristics. Key Mechanisms Underlying the Patent Claims Pseudo-ene Reagents Synthesis: The synthesis of pseudo-ene reagents forms the basis of this patent. These agents participate in highly regiospecific anionic and cationic transformations. The inventive reagents circumvent inefficient reactions characteristic of traditional methods for incorporating unnatural amino acids into proteins. Protein Modification by Ene Reaction: The e-mail sequence, specifically the Michael-type addition, provides a streamlined pathway for installing non-natural residues into the backbone of a protein's main chain. As a result of this modification, the structure and function of the target protein can be significantly altered or expanded. Patent Claims and Implications Several crucial relationships between various pseudo-ene reactions enable versatile chemical transformations, illustrated through patented compounds and derivatives. Consequently, claim interpretation requires consideration of numerous structural variations and an understanding of possible configurations and synthetic strategies connected to the pseudo-ene approach outlined in the patent. The scope of the issued patent lies in extending protein capabilities by chemical modification, and specific pseudo-ene reaction sequences highlighted in the patent create versatile options for constructing naturally evolved proteins and combining functions via reconstituted synthetic biomolecules.

Drugs Protected by US Patent 6,703,403

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

International Family Members for US Patent 6,703,403

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	225186
Austria	392895
Australia	6342096
Australia	722812
Canada	2224738
Germany	69624136
Germany	69637511